Bicycle Therapeutics plc, a pharmaceutical company specializing in bicyclic peptide technology, will present two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. The presentations include preliminary results from the Phase 1/2 Duravelo-1 study on Nectin-4-targeting zelenectide pevedotin (BT8009) plus pembrolizumab in certain urothelial cancer patients, and a Phase 2/3 study of the Bicycle® Drug Conjugate zelenectide pevedotin (BT8009) for patients with locally advanced or metastatic urothelial cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.